Αποτελέσματα Αναζήτησης
Find vaccine product codes and administration codes associated with immunization using MENVEO. Find the CPT Code, ICD-10 Code, as well as a GSK Codes Summary Sheet.
New Ready-to-Use Single Vial Presentation. Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. Menveo is now available in two presentations:
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidisserogroups A, C, Y and W-135. MENVEO is approved for use in...
26 Μαΐ 2020 · Each package of MENVEO [Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine] consists of 2 vials (one vial, containing the lyophilized MenA Conjugate Component (powder), and one vial containing the liquid MenCWY Conjugate Component (solution for injection)) as follows. Table 8:
Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
